From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone

@article{Nemeroff2005FromCR,
  title={From Clinical Research to Clinical Practice: A 4-Year Review of Ziprasidone},
  author={C. Nemeroff and J. Lieberman and P. Weiden and Philip D. Harvey and J. Newcomer and A. Schatzberg and C. Kilts and D. Daniel},
  journal={CNS Spectrums},
  year={2005},
  volume={10},
  pages={1 - 20}
}
ABSTRACT Ziprasidone is a second-generation antipsychotic that received Food and Drug Administration approval in February 2001. It has a unique receptor profile that includes high-affinity antagonist activity at dopamine D2 receptors, inverse agonist activity at serotonin (5-HT)2A receptors, agonist activity at 5-HT1A receptors, and a relatively high affinity for the serotonin and norepinephrine transporters. The 5-HT1A affinity, together with the inhibitory effect on monoamine reuptake, may… Expand
Ziprasidone in bipolar disorder
  • M. Versiani
  • Medicine
  • Expert opinion on pharmacotherapy
  • 2006
Ziprasidone in the Treatment of Affective Disorders: A Review
Ziprasidone in the treatment of mania in bipolar disorder
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
  • R. Perlis
  • Medicine
  • The American journal of managed care
  • 2007
A Comparison of Ziprasidone and Risperidone in the Long-Term Treatment of Schizophrenia: A 44-Week, Double-Blind, Continuation Study
Open-label aripiprazole in the treatment of acute bipolar depression: a prospective pilot trial.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 153 REFERENCES
Oral ziprasidone in the treatment of schizophrenia: a review of short-term trials.
  • J. Kane
  • Medicine
  • The Journal of clinical psychiatry
  • 2003
Effects of atypical antipsychotics on the syndromal profile in treatment-resistant schizophrenia.
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
...
1
2
3
4
5
...